Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 5 AND DEXTROSE 7 5 versus XARACOLL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 5 AND DEXTROSE 7 5 versus XARACOLL.
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% vs XARACOLL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking the initiation and conduction of nerve impulses. Dextrose provides caloric support.
XARACOLL (bupivacaine and meloxicam) is a fixed-dose combination product for local analgesia. Bupivacaine is an amide local anesthetic that blocks sodium ion channels, inhibiting nerve impulse conduction. Meloxicam is an NSAID that inhibits cyclooxygenase (COX) isoforms, reducing prostaglandin synthesis.
For IV administration, typical adult dose is 5-7 mg/kg intravenously as a single bolus, followed by 0.5-1 mg/kg every 5-10 minutes as needed, up to a maximum total dose of 200-300 mg. For epidural or caudal anesthesia, 15-20 mL of the 5% solution provides adequate block. For peripheral nerve block, 10-30 mL. Do not exceed 5 mg/kg per dose intravenously or 300 mg per dose by infiltration.
Adults: Single dose of 1.3 g (two microspheres) applied intraoperatively directly to the subcutaneous tissue before wound closure.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in healthy adults after intravenous administration. In patients with heart failure or hepatic impairment, half-life may be prolonged to 4-6 hours or more. After epidural administration, half-life may be slightly longer due to ongoing absorption.
Terminal elimination half-life is approximately 2-4 hours; clinical context: methadone-like opioid, prolonged half-life in elderly, renal impairment, or hepatic impairment; requires monitoring for accumulation.
Renal excretion of unchanged lidocaine and metabolites; less than 10% excreted unchanged in urine. Hepatic metabolism produces active metabolites (MEGX, GX) which are renally excreted. Biliary/fecal excretion negligible.
Primarily hepatic metabolism followed by renal excretion of metabolites; approximately 70-80% eliminated in urine (metabolites), <15% unchanged in feces via biliary excretion.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic